The Burden of Inflammatory Bowel Disease(IBD) in Japan

Abstract

Objectives: The gastrointestinal symptom score (GIS) is used in a standardised form to ascertain dyspeptic symptoms in patients with functional dyspepsia. Each symptom is included with equal importance in the overall evaluation. The objective was to derive utility weights for the ten gastrointestinal symptoms by using a best-worst scaling (BWS). The common assumption that each symptom has the same meaning for affected patients should be tested and analyzed with a stated preference approach. MethOds: In the course of a patient preference study a BWS object scaling was applied. Therefore the symptoms of the GIS were included in a questionnaire using a balanced-incomplete-block-design (BIBD). The BIBD generated a total of 15 choice sets, which each included four attributes. Results: N= 1096 affected patients were asked for their preferences regarding a treatment of functional dyspepsia and motility disorder. The results demonstrated that respondents were capable of trading between the 10 symptoms. Respondents were most sensitive to (in declining importance) the symptoms abdominal cramps (w:-1,27), vomiting (w:-1,07) and epigastric pain (w:-0,76) These symptoms were most important and thus have the greatest influence on the well-being of patients with functional dyspepsia and motility disorders. Whereas the symptoms causing the least impact are the feeling of fullness (w:0,80), early satiety (w:1,54) and loss of appetite (w:1,95). cOnclusiOns: By using a BWS the patients' preferences for prioritizing and weighting different gastrointestinal symptoms could be measured. The evaluation of the symptoms has shown, however, that the restrictive assumption of GIS reflects the reality of dyspeptic patients to a limited degree. The calculated utility weights of the patient-relevant symptoms provide an insight on the importance of individual symptoms as part of a treatment decision. The findings provide first signs of a potential modification of the established GIS. One area of potential future work is focusing on exploration of the sensitivity of the GIS. PGI30 a sysTemaTIc revIeW of The sf-36® healTh sUrvey for measUrInG healTh-relaTeD QUalITy of lIfe In PaTIenTs WITh UlceraTIve colITIsObjectives: Ulcerative colitis (UC), an inflammatory bowel disease, substantially impacts patients' health-related quality of life (HRQL). The SF-36® Health Survey (SF-36), a generic health status measure, quantifies the impact of UC on HRQL, though to-date there is no summary of evidence of its psychometric properties for this purpose. A systematic review of the literature evaluated the SF-36 as a valid and responsive measure of HRQL in UC. MethOds: We searched PubMed, EMBASE, Cochrane CENTRAL, and BIOSIS Weekly databases. Search terms included 'ulcerative colitis', 'inflammatory bowel disease', SF-36, and HRQL. English-language articles reporting SF-36 findings from UC-only samples were selected. When possible, SF-36 mean scale scores were extracted and converted to norm-based T-scores and summarized across studies. Results: Fifty-nine artic...

Cost-Effectiveness Analysis of Vedolizumab Compared with Other Biologics in Anti-TNF-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan

“…Patients with UC suffer from ulcers that generate pus and mucous, which causes inflammation and sores in the lining of the digestive tract [1]. UC is associated with significant morbidity and mortality [2]; in addition, individuals diagnosed with UC have poorer health-related quality-of-life and greater healthcare resource utilization and work productivity loss, compared with individuals without UC [3]. In Japan, the prevalence and incidence of UC have rapidly increased in recent years [4,5].…”

Cost-Effectiveness Analysis of Vedolizumab Compared With Infliximab in Anti-TNF-α-Naïve Patients With Moderate-to-Severe Ulcerative Colitis in China

“…Patients with UC have been reported to have a high disease burden, a poor quality of life, increased healthcare utilization, and decreased work productivity, leading to a high economic burden (6)(7)(8)(9). It was estimated that the mean cost of IBD was $26,255 per patient in the first year after being diagnosed in 2007-2016 in United States (10).…”